Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial
Meiyu Fang, Quanli Gao, Xiaolu Tao, Bixia Tang et al.
Citations
8 citations
Journal
Journal for ImmunoTherapy of Cancer
Topics
Cancer Immunotherapy and Biomarkers
Field-Weighted Citation Impact (FWCI)
2.26
article
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial
Meiyu Fang, Quanli Gao, Xiaolu Tao, Bixia Tang, Rong Duan, Yu Jiang, Ruixuan Luo, Shuai Zhao, Michael Lee, Yu Chen, Gang Huang, Jun Guo, Xiaoshi Zhang, Meng Qi, Rongqing Li, Zhihong Chi, Fei Zheng, Yao Li, Xiubao Ren, Meijuan Gao, Feng Li, Jing Chen, Chuanliang Cui
article en
8 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal for ImmunoTherapy of CancerVol. 12(10)
Institutions
Fujian Medical University (CN), Central South University (CN), Sun Yat-sen University (CN), Peking University (CN), Sichuan University (CN), Kunming Medical University (CN), Tianjin Medical University Cancer Institute and Hospital (CN), West China Hospital of Sichuan University (CN), Peking University Cancer Hospital (CN), Zhejiang Cancer Hospital (CN), Hunan Cancer Hospital (CN), First Affiliated Hospital of Kunming Medical University (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), Wuhan Union Hospital (CN), Shanghai Harbour Engineering Design & Research Institute (CN), Henan Cancer Hospital (CN), Sun Yat-sen University Cancer Center (CN), Fujian Provincial Cancer Hospital (CN)